Current Report Filing (8-k)
14 November 2022 - 3:21PM
Edgar (US Regulatory)
0001721484
false
0001721484
2022-11-14
2022-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): November 14, 2022
Commission File No. 001-40060
Longeveron Inc.
(Exact name of small business issuer as specified
in its charter)
| Delaware |
|
47-2174146 |
(State or other jurisdiction
of
incorporation or organization) |
|
(I.R.S. Employer
Identification Number) |
| |
|
|
1951 NW 7th Avenue,
Suite 520
Miami,
Florida |
|
33136 |
| (Address of principal executive
offices) |
|
(Zip Code) |
| (305) 909-0840 |
| (Issuer’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Class A Common Stock, par value $.001 per share |
|
LGVN |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial
Condition
On November 14, 2022, the Company announced financial
and operating results as of and for the three and nine months ended September 30, 2022 and 2021. The full text of the press release issued
in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information provided under this Form 8-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| November 14, 2022 |
|
| |
|
| |
Longeveron Inc. |
| |
|
| |
By: |
/s/ K. Christopher Min |
| |
|
Dr. K. Christopher Min
Interim Chief Executive Officer and
Chief Medical Officer |
| |
|
(principal executive officer) |
Exhibit Index
3
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
